CompletedNCT06024239
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolarity (BPD)
Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Los Alamitos and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: August 31, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 72
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06024239
- Official title
Show the full official title
A Multiple Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Subjects With Generalized Anxiety Disorder (GAD) and Subjects With Bipolar Disorder
Get this study by email
Recruitment & locations
CompletedLos Alamitos · Grayslake · Marlton
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Did this study involve medication?
Yes. The study involved medication, including ABBV-932 and Placebo for ABBV-932.
Who was this study for?
Listed age limits: 18 years to 65 years.
